Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure
Journal of Pediatric Gastroenterology and Nutrition · 31.07.2026
DOI: 10.1002/jpn3.70522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 31.07.2026. Verfasst von Emma Johnson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, American Family Children's Hospital, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Rifaximin, Catheter-Related Infections, Intestinal Failure, Catheterization, Central Venous. Die Arbeit nennt 26 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
Due to their dependence on parenteral nutrition, patients with intestinal failure (IF) are at an increased risk of central line‐associated blood stream infections (CLABSIs). Ethanol lock therapies (ELTs) reduce the incidence of CLABSIs, but ELTs work locally in the line and have limited availability in the United States. Rifaximin is a non‐absorbed, enteral antibiotic used to manage small intestinal bacterial overgrowth (SIBO). Our primary objective was to evaluate the effectiveness of rifaximin to prevent CLABSIs in pediatric IF patients.
Methods
This was a retrospective cohort study of patients with IF managed at a single pediatric center between January 2010 and December 2022. Patients in the cohort had at least 1 CLABSI prior to initiation of rifaximin. Data were collected for 12 months pre‐ and post‐rifaximin initiation. CLABSI incidences were compared using Poisson regression with a log transformation.
Results
Thirty‐three patients were included. The observed incidence of CLABSI for all patients in our sample, before and after rifaximin initiation, was 10.2 (8.2, 12.7) and 7.3 (5.8, 9.2) per 1000 central line days, respectively, p = 0.03. Subgroup analysis showed patients who received rifaximin without ELT had signification reduction in CLABSIs, 8.3 versus 3.0 ( p < 0.001). There were no statistically significant differences in the proportion of gram‐positive or gram‐negative bacteria or yeast isolated before and after rifaximin.
Conclusions
Children with IF who were treated with rifaximin experienced fewer CLABSI events, suggesting that rifaximin is a viable option for CLABSI prophylaxis in pediatric IF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, American Family Children's Hospital, Madison, Wisconsin, USA.
- Division of Pharmacy, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Division of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Emma Johnson
Förderung
- None
Zitieren
APA
Johnson, E., Konicek, C., Lamb, N., Fishbein, J., Jhaveri, R., & Cohran, V. (2026). Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70522
Vancouver
Johnson E, Konicek C, Lamb N, Fishbein J, Jhaveri R, Cohran V. Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70522
BibTeX
@article{Johnson2026,
author = {Johnson, Emma and Konicek, Claire and Lamb, Nathan and Fishbein, Joseph and Jhaveri, Ravi and Cohran, Valeria},
title = {Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70522}
}
EUVIMED